MINI FUTURE LONG - ORION B | Real-time Bid/Ask 11:57:04 20/05/2024 BST | ||
| 0.87 EUR / 0.88 EUR | +5.42% |
|
| 1 month | +154.55% | ||
| 3 months | -21.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 0.87 | +4.82% |
| 17/05/24 | 0.84 | -3.45% |
| 16/05/24 | 0.87 | +4.82% |
| 15/05/24 | 0.83 | +1.22% |
| 14/05/24 | 0.82 | +6.49% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 09:53 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | MB1H39 |
| ISIN | DE000MB1H395 |
| Date issued | 15/12/2022 |
| Strike | 29.24 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.71 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.01 € |
| Spread % | 1.14% |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.69
EUR
Average target price
39
EUR
Spread / Average Target
+3.48%
- Stock Market
- Certificates
- Certificat
